A custom virtual reality training solution for ophthalmologic surgical clinical trials

AbstractWe present a summary of the development and clinical use of two custom designed high-fidelity virtual-reality simulator training platforms. This simulator development program began in 2016 to support the phase III clinical trial Archway (ClinicalTrials.gov identifier, NCT03677934) intended to evaluate the Port Delivery System (PDS) developed by Genentech Inc. and has also been used to support additional clinical trials. The two simulators address two specific ophthalmic surgical procedures required for the successful use of PDS and provide state-of-the-art physical simulation models and graphics. The simulators incorporate customized active haptic feedback input devices that approximate different hand pieces including a custom hand piece specifically designed for PDS implantation. We further describe the specific challenges of the procedure and the development of corresponding training strategies realized within the simulation platform.

Download Full-text

Virtual Reality: A Tool for Assembly?

Presence Teleoperators & Virtual Environments ◽

10.1162/105474600566970 ◽

2000 ◽

Vol 9 (5) ◽

pp. 486-496 ◽

Cited By ~ 28

Author(s):

A. C. Boud ◽

C. Baber ◽

S. J. Steiner

Keyword(s):

Virtual Reality ◽

Virtual Environments ◽

Haptic Feedback ◽

Object Manipulation ◽

Task Planning ◽

Input Devices ◽

Assembly Task ◽

Current Input

This paper reports on an investigation into the proposed usability of virtual reality for a manufacturing application such as the assembly of a number of component parts into a final product. Before the assembly task itself is considered, the investigation explores the use of VR for the training of human assembly operators and compares the findings to conventionally adopted techniques for parts assembly. The investigation highlighted several limitations of using VR technology. Most significant was the lack of haptic feedback provided by current input devices for virtual environments. To address this, an instrumented object (IO) was employed that enabled the user to pick up and manipulate the IO as the representation of a component from a product to be assembled. The reported findings indicate that object manipulation times are superior when IOs are employed as the interaction device, and that IO devices could therefore be adopted in VEs to provide haptic feedback for diverse applications and, in particular, for assembly task planning.

Download Full-text

Lack of transfer of skills after virtual reality simulator training with haptic feedback

Minimally Invasive Therapy & Allied Technologies ◽

10.1080/13645706.2017.1319866 ◽

2017 ◽

Vol 26 (6) ◽

pp. 346-354 ◽

Cited By ~ 24

Author(s):

Cecilie Våpenstad ◽

Erlend Fagertun Hofstad ◽

Lars Eirik Bø ◽

Esther Kuhry ◽

Gjermund Johnsen ◽

...

Keyword(s):

Virtual Reality ◽

Haptic Feedback ◽

Simulator Training ◽

Virtual Reality Simulator ◽

Transfer Of Skills

Download Full-text

Virtual Reality approaches for evacuation simulation of various disasters

Collective Dynamics ◽

10.17815/cd.2020.93 ◽

2020 ◽

Vol 5 ◽

pp. A93

Author(s):

Naohiro Takeichi ◽

Takeshi Katagiri ◽

Harumi Yoneda ◽

Shusaku Inoue ◽

Yusuke Shintani

Keyword(s):

Virtual Reality ◽

Physical Simulation ◽

Numerical Models ◽

Simulation Models ◽

Performance Based Design ◽

Disaster Prevention ◽

Evacuation Simulation ◽

Building Information Modelling ◽

Realistic Situation ◽

Building Information

This paper presents a virtual reality (VR) system of evacuation in the cases of various disasters. We considered a combination of disasters under realistic scenarios. Disaster simulations by numerical models were imported into the VR system to express a realistic situation. Not only disaster experts but also designers and non-professionals are able to share realistic experiences for escape from the disasters. This system is useful for performance-based design, planning of escape, disaster prevention, evacuation drill etc. The VR system consists of Building Information Modelling, physical simulation models for disasters and human behaviour’s simulation.

Download Full-text

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

Gastroenterology ◽

10.1016/s0016-5085(01)81411-6 ◽

2001 ◽

Vol 120 (5) ◽

pp. A284-A284

Author(s):

B NAULT ◽

S SUE ◽

J HEGGLAND ◽

S GOHARI ◽

G LIGOZIO ◽

...

Keyword(s):

Clinical Trials ◽

Irritable Bowel Syndrome ◽

Phase Iii ◽

Phase Iii Clinical Trials ◽

Irritable Bowel ◽

Rome I

Download Full-text

Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials

Seminars in Oncology ◽

10.1053/sonc.2001.28598 ◽

2001 ◽

Vol 28 (6) ◽

pp. 620-625 ◽

Cited By ~ 4

Author(s):

Pierre Falardeau ◽

Pierre Champagne ◽

Patrick Poyet ◽

Claude Hariton ◽

[Eacute]ric Dupont

Keyword(s):

Clinical Trials ◽

Phase Iii ◽

Phase Iii Clinical Trials ◽

Naturally Occurring ◽

Antiangiogenic Drug

Download Full-text

Treatment and secondary prevention of venous thromboembolism in cancer patients

Onkologische Welt ◽

10.1055/s-0038-1630173 ◽

2012 ◽

Vol 03 (03) ◽

pp. 121-125

Author(s):

I. Pabinger ◽

C. Ay

Keyword(s):

Clinical Trials ◽

Venous Thromboembolism ◽

Cancer Patients ◽

Oral Anticoagulants ◽

Factor Xa ◽

New Oral Anticoagulants ◽

Phase Iii ◽

Patients With Cancer ◽

Potential Use

SummaryCancer is a major and independent risk factor of venous thromboembolism (VTE). In clinical practice, a high number of VTE events occurs in patients with cancer, and treatment of cancerassociated VTE differs in several aspects from treatment of VTE in the general population. However, treatment in cancer patients remains a major challenge, as the risk of recurrence of VTE as well as the risk of major bleeding during anticoagulation is substantially higher in patients with cancer than in those without cancer. In several clinical trials, different anticoagulants and regimens have been investigated for treatment of acute VTE and secondary prophylaxis in cancer patients to prevent recurrence. Based on the results of these trials, anticoagulant therapy with low-molecular-weight heparins (LMWH) has become the treatment of choice in cancer patients with acute VTE in the initial period and for extended and long-term anticoagulation for 3-6 months. New oral anticoagulants directly inhibiting thrombin or factor Xa, have been developed in the past decade and studied in large phase III clinical trials. Results from currently completed trials are promising and indicate their potential use for treatment of VTE. However, the role of the new oral thrombin and factor Xa inhibitors for VTE treatment in cancer patients still has to be clarified in further studies specifically focusing on cancer-associated VTE. This brief review will summarize the current strategies of initial and long-term VTE treatment in patients with cancer and discuss the potential use of the new oral anticoagulants.

Download Full-text

Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome

Current Drug Metabolism ◽

10.2174/1389200221666200425211139 ◽

2020 ◽

Vol 21 (2) ◽

pp. 79-88 ◽

Cited By ~ 1

Author(s):

Pankaj Mandpe ◽

Bala Prabhakar ◽

Pravin Shende

Keyword(s):

Clinical Trials ◽

Overactive Bladder ◽

Adverse Effects ◽

Symptomatic Relief ◽

Phase Iii ◽

Overactive Bladder Syndrome ◽

Modified Release ◽

Blurred Vision ◽

Antimuscarinic Drugs ◽

Tablet Dosage

Background: Overactive bladder syndrome is a broadly occurring urological disorder with a distressing impact on the quality of life. The commonly used antimuscarinic drugs show poor patient compliance because of unsatisfactory potency, tolerability and high occurrence of adverse effects such as dry mouth, blurred vision, constipation, dizziness etc. Mirabegron is the first approved β3-adrenoreceptor agonist, used as mono or in combination therapies for overactive bladder syndrome. Objective: The present review provides an insight into the mechanism, pharmacokinetics, toxicokinetics, clinical trials and the development of various conventional and modified-release dosage forms of mirabegron for the treatment of overactive bladder syndrome. Results: The clinical trials of phase II and phase III of mirabegron demonstrated symptomatic relief from the overactive bladder without disturbing the micturition cycle. To date, mirabegron showed promising results for safety, tolerability and efficacy in patients with overactive bladder syndrome. The modified-release tablet dosage form of mirabegron appear to be a proficient and suitable replacement for antimuscarinics and revealed the tremendous potential to overcome the adverse effects of conventional antimuscarinic drugs like Oxybutyline chloride ER, Detrol LA, VESIcare, etc. Conclusion: Mirabegron shows a distinct mode of action, i.e., targeting β3-adrenoreceptors and improving bladder storage without altering void contractions. The limited side effects, high safety, efficacy and tolerability of mirabegron present an adequate substitute to antimuscarinics. However, long-term analysis and clinical studies are prerequisites for assessing the safety, tolerability and efficacy profile of mirabegron.

Download Full-text

LIRKIS Global Collaborative Virtual Environments: Current State and Utilization Perspective

Open Computer Science ◽

10.1515/comp-2020-0124 ◽

2020 ◽

Vol 11 (1) ◽

pp. 99-106

Author(s):

Marián Hudák ◽

Štefan Korečko ◽

Branislav Sobota

Keyword(s):

Virtual Reality ◽

Virtual Environments ◽

Smart Devices ◽

Collaborative Virtual Environments ◽

Web Based ◽

Smart Client ◽

Input Devices ◽

User Input ◽

History Of ◽

Shared Virtual Environments

AbstractRecent advances in the field of web technologies, including the increasing support of virtual reality hardware, have allowed for shared virtual environments, reachable by just entering a URL in a browser. One contemporary solution that provides such a shared virtual reality is LIRKIS Global Collaborative Virtual Environments (LIRKIS G-CVE). It is a web-based software system, built on top of the A-Frame and Networked-Aframe frameworks. This paper describes LIRKIS G-CVE and introduces its two original components. The first one is the Smart-Client Interface, which turns smart devices, such as smartphones and tablets, into input devices. The advantage of this component over the standard way of user input is demonstrated by a series of experiments. The second component is the Enhanced Client Access layer, which provides access to positions and orientations of clients that share a virtual environment. The layer also stores a history of connected clients and provides limited control over the clients. The paper also outlines an ongoing experiment aimed at an evaluation of LIRKIS G-CVE in the area of virtual prototype testing.

Download Full-text

Animal and Human Vaccines against West Nile Virus

Pathogens ◽

10.3390/pathogens9121073 ◽

2020 ◽

Vol 9 (12) ◽

pp. 1073

Author(s):

Juan-Carlos Saiz

Keyword(s):

Clinical Trials ◽

West Nile Virus ◽

Vaccine Development ◽

Phase Iii ◽

West Nile ◽

Specific Therapy ◽

Phase Iii Clinical Trials ◽

Neuroinvasive Disease ◽

The Us ◽

The Status

West Nile virus (WNV) is a widely distributed enveloped flavivirus transmitted by mosquitoes, which main hosts are birds. The virus sporadically infects equids and humans with serious economic and health consequences, as infected individuals can develop a severe neuroinvasive disease that can even lead to death. Nowadays, no WNV-specific therapy is available and vaccines are only licensed for use in horses but not for humans. While several methodologies for WNV vaccine development have been successfully applied and have contributed to significantly reducing its incidence in horses in the US, none have progressed to phase III clinical trials in humans. This review addresses the status of WNV vaccines for horses, birds, and humans, summarizing and discussing the challenges they face for their clinical advance and their introduction to the market.

Download Full-text

Telemanipulation of an Articulated Robotic Arm using a Commercial Virtual Reality Controller

Current Directions in Biomedical Engineering ◽

10.1515/cdbme-2020-3033 ◽

2020 ◽

Vol 6 (3) ◽

pp. 127-130

Author(s):

Max B. Schäfer ◽

Kent W. Stewart ◽

Nico Lösch ◽

Peter P. Pott

Keyword(s):

Virtual Reality ◽

Real Time ◽

Robotic Arm ◽

Input Device ◽

Robot Assisted ◽

Promising Alternative ◽

Input Devices ◽

Current Input ◽

Current Systems ◽

Robot Assisted Surgery

AbstractAccess to systems for robot-assisted surgery is limited due to high costs. To enable widespread use, numerous issues have to be addressed to improve and/or simplify their components. Current systems commonly use universal linkage-based input devices, and only a few applicationoriented and specialized designs are used. A versatile virtual reality controller is proposed as an alternative input device for the control of a seven degree of freedom articulated robotic arm. The real-time capabilities of the setup, replicating a system for robot-assisted teleoperated surgery, are investigated to assess suitability. Image-based assessment showed a considerable system latency of 81.7 ± 27.7 ms. However, due to its versatility, the virtual reality controller is a promising alternative to current input devices for research around medical telemanipulation systems.

Download Full-text